GBT440: Ph I Basecamp (GBT440-011) started

Global Blood Therapeutics began the open-label, U.S. Phase I Basecamp (GBT440-011) trial to evaluate 900 mg oral GBT440 once daily for 14 days in 12 healthy volunteers....